期刊文献+

VEGF基因RNA干扰质粒的构建与鉴定 被引量:3

Construction and Identification of VEGF Gene RNA Interference Recombinant Plasmid
下载PDF
导出
摘要 目的构建干扰血管内皮生长因子(vascular endothelial growth factor,VEGF)基因RNA表达的重组质粒。方法设计3组针对VEGF基因的核糖核酸干扰(RNA interference,RNAi)序列,应用基因重组技术克隆入载体pcDNA3.1中,重组质粒分别命名为pcDNA3.1-VEGF-LH1、pcDNA3.1-VEGF-LH2和pcDNA3.1-VEGF-LH3,用DNA直接测序法和双酶切法鉴定构建的重组质粒。结果 DNA测序证实克隆入载体pcDNA3.1(-)中的序列正确,双酶切证实RNA干扰序列正确插入载体pcDNA3.1(-)。结论成功构建针对VEGF基因的RNAi质粒,为进一步研究该RNAi质粒在脉络膜新生血管形成中的作用奠定了基础。 Objective To construct the recombinant plasmid which interferes the RNA expression of vascular endothelial growth factor(VEGF) gene.Methods Three groups of RNA interference(RNAi) sequences were designed according to VEGF gene of pigment rats.The recombination technology was applied to insert all RNA interference sequences into the plasmid carrier pcDNA3.1(-).The recombinant plasmids were named pcDNA3.1-VEGF-LH1,pcDNA3.1-VEGF-LH2 and pcDNA3.1-VEGF-LH3.These recombinant plasmids were identified by DNA direct sequencing method and double enzyme appraisal method.Results DNA sequencing confirmed that the sequences cloning into the plasmid carrier pcDNA3.1(-) were correct.Double enzyme appraisal affirmed that the RNA interference sequences were inserted into carrier pcDNA3.1(-) correctly.Conclusion The VEGF gene RNA interference recombination plasmids are successfully constructed,which lays the foundation to further study the function of the RNAi plasmid in the whole process of choroidal neovascularization(CNV) generation.
出处 《华南国防医学杂志》 CAS 2013年第5期299-304,共6页 Military Medical Journal of South China
基金 湖北省自然科学基金项目(2011CDB018)
关键词 血管内皮生长因子 RNA干扰 重组质粒 脉络膜新生血管 Vascular endothelial growth factor RNA interference Recombinant plasmid Choroidal neovascularization
  • 相关文献

参考文献23

二级参考文献79

  • 1何孟栖,陈利国.血管内皮细胞原代培养方法的改良及应用[J].陕西医学杂志,2004,33(7):581-582. 被引量:5
  • 2颜世龙,梁丹,林妙丽,李永平,汪振芳.碱烧伤大鼠角膜新生血管模型的初步探索[J].眼科学报,2005,21(4):165-169. 被引量:16
  • 3王应利,惠延年.血管生成素1对视网膜新生血管形成的作用及其机制[J].中华眼底病杂志,2007,23(2):149-152. 被引量:3
  • 4Edelman JL , Castro MR , Wen Y. Correlation of VEGF expression by leuko2cytes with the growth and regression of blood vessels in the rat cornea. Invest Ophthalmod Vis Sci, 1999 ,40 : 1112-1123.
  • 5Shiose S, Sakamoto T, Yoshikawa H, et al. Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma. Invest Ophthalmol Vis Sci, 2000,41 : 2395- 2403.
  • 6Hotz HG, Hines OJ, Masood R, et al. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery, 2005,137:192-199.
  • 7Tolentino MJ, Brucker AJ, Fosnot J, et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina, 2004,24 : 132-138.
  • 8Nakamura H, Siddiqui SS, Shen X, et al. RNA interference targeting transforming growth factor-beta type Ⅱ receptor suppresses ocular inflammation and fibrosis. Mol Vis, 2004,10 : 703-711.
  • 9Filleurs, Courtin A, Ait-Si-Alis, et al. SiRNA-mediated inhibition of Vascular Endothelial Growth Factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Research, 2003,63 : 3919- 3922.
  • 10Gohto Y, Obana A, Kaneda K, et al. Photodynamic effect of a new photosensitizer ATX-S10 on corneal neovascularization. Exp Eye Res, 1998,67:313-322.

共引文献11

同被引文献25

  • 1Robison WG, Lawer NM, Jacot JL. Efficacy of treatment after measurable diabetic like retiopathy in galactese fedrats [J].Invest Ophthalmol Vis Sei, 1997,38 (6) :1066-1072.
  • 2Carter JG, Cherry J, Williams K, et al. Splicing factor polymor- phisms, the control of VEGF isoforms and association with an- giogenic eye disease[J].Curr Eye Res, 2011, 36 (4) : 328-335.
  • 3Vailati FB, Crispim D, Sortica DA, et al.The C allele of -634G/C polymorphism in the VEGFA gene is associated with increased VEGFA gene expression in human retinal tissue[J]. Invest Opthalmol Vis Sci, 2012,53 (10) : 6411-6415.
  • 4Arevalo JF, Wu L, Sanchez JG, et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months fol- low-up[J].Eye, 2007,23(1) : 117-123.
  • 5Hasanreisoglu M, Weinberger D, Mimouni K, et al. Intravitreal bevaeizumab as adjunct for neovacular glaueoma[J].Eur J Oph thalmol,2009,19(4) :607-612.
  • 6Mohan N, Monickaraj F, Balasubramanyam M, et al. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative dia- betic retinopathy[J].J Diabetes Complication, 2012,26 (5) : 435- 441.
  • 7Wu H, Jiang J, Wu J, et al. High glucose attenuates insulin-in duced VEGF expression in bovine retinal microvreaseular endo- thelial cells[J].Eye,2010,24(1 ) : 145- 151.
  • 8Hutchings H, Maitre-Boube M, Tombran-Tink J,et al.Pigment epithelium-derived factor exerts opposite effects on endothelial cells of different phenotypes[J].Biochem Biophys Res Commun, 2002,294(4) : 764-769.
  • 9Dispenzieri A. How I treat POEMS syndrome[J]. Blood, 2012,119(24):5650-5658.
  • 10Dispenzieri A. POEMS syndrome[J]. Blood Rev, 2007,21(6):285-299.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部